EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

September 22, 2016

Primary Completion Date

December 20, 2018

Study Completion Date

December 20, 2018

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

Tocilizumab

Subcutaneous Tocilizumab according to approved label.

Trial Locations (26)

11521

Rheumatology Private Practice, Athens

14527

General Hospital of Athens KAT, Rheumatology, Athens

17673

Rheumatology Private Practice, Kalithea, Athens

19200

Rheumatology Private Practice, Eleusina

26221

Rheumatology Private Practice, Pátrai

26443

Olympion Medical Center of Patras, Internal Medicine Clinic, Pátrai

38221

Rheumatology Private Practice, Volos

54621

Rheumatology Private Practice, Thessaloniki

59100

Rheumatology Private Practice, Véroia

62122

Rheumatology Private Practice, Serres

65500

General Hospital of Kavala; Rheumatology, Kavala

66132

Private Practice Rheumatology, Papadimitriou, Drama

301 00

Private Practice Rheumatology, Merantzis, Agrinio

Unknown

Rheumatology Private Practice, Athens

Private Practice Rheumatology, Stavropoulos, Áno Patísia

Rheumatology Private Practice, Kifissia

General Hospital Agios Pavlos, Thessaloniki

Rheumatology Private Practice, Thessaloniki

731 00

Rheumatology Private Practice, Chania

124 62

ATTIKO Hospital_4th University Internal Medicine Clinic, Haidari

453 33

Private Practice Rheumatology, Georgiadis, Ioannina

431 00

Private Practice Rheumatology, Kotrotsios, Karditsa

412 21

Private Practice Rehumatology, Ziogas, Larissa

811 00

General Hospital of Mytilini, Rheumatology, Mytilene

171 21

Private Practice Rheumatology, Trontzas, Néa Smýrni

621 22

Private Practice Rheumatology, Psaltis, Serres

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02648035 - EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter